NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
86.52
-0.87 (-1.00%)
As of 12:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close87.39
Open86.62
Bid86.65 x 900
Ask86.67 x 800
Day's Range86.25 - 86.78
52 Week Range72.30 - 94.19
Volume2,090,439
Avg. Volume2,735,530
Market Cap201.333B
Beta (3Y Monthly)0.84
PE Ratio (TTM)15.16
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.98 (3.42%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • 2 Sets of Disasters Biotech Will Pay For in 2019
    Motley Foolyesterday

    2 Sets of Disasters Biotech Will Pay For in 2019

    Here's how calamities we witnessed in 2018 will hound biotech investors in the new year.

  • Zacks3 days ago

    Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

    AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

  • Zacks4 days ago

    J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study

    J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.

  • Benzinga4 days ago

    The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...

  • Reuters5 days ago

    J&J says its psoriasis drug superior to Novartis treatment in study

    Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study. After 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis's Cosentyx, J&J said.

  • Zacks6 days ago

    Teva (TEVA) Stock Poised to Record Big Gains in 2019?

    Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • Here is What Hedge Funds Think About Novartis AG (NVS)
    Insider Monkey7 days ago

    Here is What Hedge Funds Think About Novartis AG (NVS)

    The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]

  • Zacks7 days ago

    Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend

    Amgen (AMGN) hikes its quarterly dividend by 10%.

  • Generic drugmaker Sandoz to sell alternative to EpiPen injectors
    MarketWatch11 days ago

    Generic drugmaker Sandoz to sell alternative to EpiPen injectors

    Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.

  • Reuters11 days ago

    Novartis to launch Adamis' EpiPen rival in U.S. next year

    Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.

  • Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
    Zacks11 days ago

    Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

    Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

  • Roche's Kadcyla Halves Death Risk in Breast Cancer Study
    Zacks11 days ago

    Roche's Kadcyla Halves Death Risk in Breast Cancer Study

    Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

  • Roche's Tecentriq Combination Gets Priority Review by FDA
    Zacks12 days ago

    Roche's Tecentriq Combination Gets Priority Review by FDA

    The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.

  • Incyte (INCY) Announces Positive Data on Jakafi for GVHD
    Zacks13 days ago

    Incyte (INCY) Announces Positive Data on Jakafi for GVHD

    Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.

  • Gilead (GILD) Announces Data on CAR T Therapy Candidate
    Zacks13 days ago

    Gilead (GILD) Announces Data on CAR T Therapy Candidate

    Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

  • FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
    Zacks13 days ago

    FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

    The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

  • Ajovy Is a New Growth Driver for Teva Pharmaceutical
    Market Realist13 days ago

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.

  • Global Blood Therapeutics' Voxelotor on Faster Approval Path
    Zacks13 days ago

    Global Blood Therapeutics' Voxelotor on Faster Approval Path

    Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.

  • Glaxo to Sell India's Popular Horlicks Brand to Unilever
    Zacks13 days ago

    Glaxo to Sell India's Popular Horlicks Brand to Unilever

    Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.

  • Reuters13 days ago

    Novartis's new treatment for hives outperforms Xolair in trials

    Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives. Xolair is sold by both Novartis and Roche, but has lost patent protection in Europe and the United States, leaving it exposed to rivals who are developing copies of the biological drug. Novartis said it now plans two Phase III studies for ligelizumab with more than 2,000 patients who suffer from chronic spontaneous urticaria (CSU), an autoimmune disease that causes persistent itchy reddish welts on the skin.

  • Reuters14 days ago

    UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients

    Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. The question of how long patients will benefit from Yescarta and other therapies in an expensive new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, has been a key topic at the annual meeting of the American Society of Hematology (ASH) in San Diego. Both Yescarta and rival Kymriah from Novartis AG have U.S. prices for lymphoma of $373,000 for health insurers including the Medicare government program for seniors.